AegirBio AB has received National Institutes of Health (NIH) programmatic approval for an accessibility project to be funded under the NIH/NIBIB?s Rapid Acceleration of Diagnostics (RADx) initiative. In the first phase of the project, the company can receive up to approximately USD 1 million in milestone based payments with the potential for follow on funding if key feasibility milestones are met. Funding is dependent on reaching the milestones.

The company had applied in response to a call for COVID-19 home tests accessible to people with disabilities with a project based on emerging saliva testing platform.